Category: Accuray Inc.
Medical device company Accuray explains its action to remove 2 potentially defective components of its flagship CyberKnife radiosurgery platform.
Radiosurgery devices maker Accuray (NSDQ:ARAY) released an official statement on the recall of a pair of components of its CyberKnife radiosurgery systems, warning that the devices were not manufactured to standard.
Holaira says it raised $10 million from existing investors for its lung denervation system to treat chronic obstructive pulmonary disease.
Medical device company Holaira said it drummed up $10 million, changed its name and moved its headquarters.
Formerly known as Innovative Pulmonary Solutions, Holaira said it plans to use the Series C round to develop its minimally invasive devices to treat obstructive lung disease. All of Holaira's existing backers participated, namely Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, and Versant Ventures.
Sarif Biomedical sues medical device company Accuray for patent infringement over the latter's CyberKnife cancer treatment device.
Sarif Biomedical accused Accuray (NSDQ:ARAY) of infringing 1 of its patents with the CyberKnife radiosurgery device for cancer, which uses targeted radiation blasts to destroy tumor cells.
Tool, Texas-based Sarif's patent covers ""Computer-Assisted Microsurgery Methods and Equipment." The medical device company alleges that Accuray's device trespasses on that intellectual property, according to the lawsuit.
On the heels of gaping losses and a more than 25% sales decline, Accuray announces plans for a $75 million debt round.
Accuray (NSDQ:ARAY) plans to issue $75 million worth of convertible senior notes as it gears up to restructure its business after a year of widening losses.
The Sunnyvale, Calif.-based medical device company said it will use the proceeds from the offering of debt due Feb. 1, 2018, to shore up its balance sheet.
Accuray's fiscal 2nd quarter sales plunge and its losses gape wider, sending share prices down almost 10% today.
Accuray (NSDQ:ARAY) shares lost nearly 10% today after the medical device company reported soaring losses and a nearly 27% sales slide for its fiscal 2nd quarter.
The Sunnyvale, Calif.-based company, which makes radiation oncology equipment, posted losses of $29.2 million, or 40¢ per share, on sales of $77.8 million for the 3 months ended Dec. 31, 2012. That amounts to a 180.8% increase in losses and a 26.9% top-line reduction.
New Accuray president & CEO Joshua Levine plans to cut about 13% of the company's workers in efforts to execute a "strategic transformation" that will save the company about $40 million per year.
Sunnyvale, Calif.-based radiotherapy devices maker Accuray (NSDQ:ARAY) will lay off about 13% of its global workforce, mostly in the U.S., the company reported this week.
Accuray made the announcement upon releasing its preliminary 2nd quarter 2013 financial results, in which the company noted a 45%-50% decline in product revenue.